The Gastrointestinal Cancer Channel is supported with funding from Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESMO 2021 | DESTINY-Gastric02: T-Dxd as a second-line treatment for HER2-positive gastric cancer
Elizabeth Smyth, MD, Cambridge University Hospitals, Cambridge, UK, summarises the rationale and results of the DESTINY-Gastric02 trial (NCT04014075). This was a non-randomised Phase II trial of trastuzumab deruxtecan (T-Dxd) as a second-line treatment for patients with HER2-positive gastric cancer. The overall response rate, which was the primary endpoint, was 38%, with a duration of response of more than 8 months. The treatment was well-tolerated and encouraging results were achieved. This interview took place at the European Society for Medical Oncology (ESMO) 2021 congress.
Disclosures
Dr Smyth reports personal financial interests (lecture honoraria, advisory boards, travel support) from AMAL Therapeutics, Astra Zeneca, Astellas, Beigene, BMS, Celgene, Elsevier, Everest Clinical Research, Five Prime Therapeutics, Gritstone Oncology, Merck, Pfizer, Roche, Servier, Zymeworks.
